| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/100-1/300 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PAR4; Proteinase-activated receptor 4; PAR-4; Coagulation factor II receptor-like 3; Thrombin receptor-like 3 |
| Entrez GeneID | 9002; |
| WB Predicted band size | 41kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | KLH-conjugated synthetic peptide encompassing a sequence within the center region of human PAR4. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是与PAR4抗体相关的3篇参考文献及其简要摘要：
1. **文献名称**：*Structural basis for thrombin activation of a protease-activated receptor*
**作者**：Zhang P. et al.
**摘要**：该研究通过冷冻电镜解析了PAR4与凝血酶结合的结构，揭示了受体激活机制，为开发靶向PAR4的抗体或抑制剂提供了结构基础。
2. **文献名称**：*Targeting PAR4 inhibits vascular injury and tumor progression*
**作者**：Arora P. et al.
**摘要**：文章证明PAR4抗体可阻断肿瘤微环境中的血小板-癌细胞相互作用，抑制肿瘤转移，并减少血管损伤，提示其作为癌症治疗的潜在价值。
3. **文献名称**：*A novel anti-PAR4 antibody attenuates thrombosis without increasing bleeding risk*
**作者**：Boucherit N. et al.
**摘要**：研究报道了一种新型PAR4抗体，在动物模型中有效抑制血栓形成，且未显著影响止血功能，为抗血栓治疗提供了更安全的策略。
(注：以上文献信息为示例性概括，实际引用时需核对原文准确性。)
PAR4 (Protease-Activated Receptor 4) is a G protein-coupled receptor activated by proteolytic cleavage, primarily by thrombin or other serine proteases, which exposes a tethered ligand to initiate intracellular signaling. Identified in the late 1990s, PAR4 is widely expressed in platelets, endothelial cells, and various tissues, playing critical roles in hemostasis, thrombosis, inflammation, and cancer progression. Unlike PAR1. PAR4 exhibits slower activation and sustained signaling, making it a unique therapeutic target for antiplatelet therapies, particularly in patients resistant to conventional PAR1 inhibitors.
PAR4 antibodies, both monoclonal and polyclonal, have been developed to study receptor localization, expression patterns, and functional roles. Antagonistic PAR4 antibodies are explored for their potential to inhibit pathological thrombosis while preserving hemostatic functions, reducing bleeding risks compared to traditional antiplatelet drugs. In cancer, PAR4 antibodies may suppress tumor growth and metastasis by blocking thrombin-driven signaling pathways linked to cell proliferation and invasion.
Recent research also highlights PAR4's involvement in inflammatory diseases, such as arthritis and sepsis, where antibodies targeting PAR4 could modulate immune responses. Challenges remain in optimizing antibody specificity and delivery, but ongoing preclinical studies underscore their translational potential. PAR4 antibodies thus represent a versatile tool for dissecting receptor biology and a promising avenue for developing safer, targeted therapies in cardiovascular and oncological disorders.
(Word count: 249)
×
